June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Biodegradable injectable sheet as transscleral drug delivery system
Author Affiliations & Notes
  • Nobuhiro Nagai
    Graduate School of Medicine, Tohoku University, Sendai, Japan
  • Zhaleh Kashkouli Nezhad
    Graduate School of Medicine, Tohoku University, Sendai, Japan
  • Saaya Saijo
    Graduate School of Medicine, Tohoku University, Sendai, Japan
  • Hirokazu Kaji
    Graduate School of Engineering, Tohoku University, Sendai, Japan
  • Matsuhiko Nishizawa
    Graduate School of Engineering, Tohoku University, Sendai, Japan
  • Toru Nakazawa
    Graduate School of Medicine, Tohoku University, Sendai, Japan
  • Toshiaki Abe
    Graduate School of Medicine, Tohoku University, Sendai, Japan
  • Footnotes
    Commercial Relationships   Nobuhiro Nagai, None; Zhaleh Nezhad, None; Saaya Saijo, None; Hirokazu Kaji, None; Matsuhiko Nishizawa, None; Toru Nakazawa, None; Toshiaki Abe, None
  • Footnotes
    Support  Basic Science and Platform Technology Program for Innovative Biological Medicine, Japan and JSPS KAKENHI Grant Number 15H03015, Japan
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4464. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Nobuhiro Nagai, Zhaleh Kashkouli Nezhad, Saaya Saijo, Hirokazu Kaji, Matsuhiko Nishizawa, Toru Nakazawa, Toshiaki Abe; Biodegradable injectable sheet as transscleral drug delivery system. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4464.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the in vitro and in vivo drug release of a biodegradable injectable sheet made of cross-linked chitosan and gelatin mixture.

Methods : Gelatin and chitosan were solved in water and 1% acetic acid at concentrations of 5 wt% and 2.5 wt%, respectively. Then, 5 wt% gelatin and 2.5 wt% chitosan was mixed at the ratio of 3 : 2 (vol). The drug was mixed with the 3 wt% gelatin/1 wt% chitosan mixture. Fluorescein isothiocyanate (FITC), FITC-labeled dextran 150 kDa (FD150), and FITC-labeled albumin (FITC-ALB) were used as drugs. Immedeately after adding water soluble carbodiimide in the gelatin/chitosan/drug mixture at final concentration of 10 mg/mL, 3 μL of the mixture was cast in the polydimethylsilane (PDMS) mold (internal diameter; 2.76 mm, depth; 0.5 mm). Then, the cross-linked gels were dried for 1 hour at room temperutere to make flexible sheets. The sheets were incubated in phosphate buffered saline (PBS) at 37 degrees C. The drug concentration in PBS were measured spectrofluorometrically. The sheets were placed on the sclerae of rats and cryo-sections of the eyes were observed by fluorescent microscope. HE staining was conducetd to evaluate the biodegradation of the sheets.

Results : Drug release from the sheets was confirmed in vitro for 4 weeks. The sheet can be ejected from 21 G needle with 1 mL syringe. Fluorescence of released FITC, FD150, and FITC-ALB was detected in the sclera, choroid, and retinal pigment epithelium for 2 weeks implantation. The sheets were gradually biodegraded for 2 weeks.

Conclusions : The biodegradable injectable sheet consisted of cross-linked gelatin/chitosan formulation was developed. The sheets could be injected through a conventional syringe needle into water to recover its original shape, and was capable of sustained release of protein type drugs. It therefore provides the possibility of minimally invasive transplantation into episclera space, and could provide better therapeutic outcomes and reduce possible side effects.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×